The updated prescribing information now includes 240-week results from the STARTMRK study, the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-nave adult patients with HIV-1 infection.
http://www.pmpnews.com/news/fda-approves-new-us-labeling-isentress-raltegravir-include-240-week-results-startmrk-study-isen
http://www.pmpnews.com/news/fda-approves-new-us-labeling-isentress-raltegravir-include-240-week-results-startmrk-study-isen
No comments:
Post a Comment